Palbociclib and cetuximab compared with placebo and cetuximab in platinum-resistant, cetuximab-naïve, human papillomavirus-unrelated recurrent or metastatic head and neck squamous cell carcinoma: A double-blind, randomized, phase 2 trial

Phase 2 ◽

Double Blind ◽

Phase 2 Trial ◽

nab-Paclitaxel and cisplatin followed by cisplatin and radiation (Arm 1) and nab-paclitaxel followed by cetuximab and radiation (Arm 2) for locally advanced head and neck squamous-cell carcinoma: a multicenter, non-randomized phase 2 trial

Medical Oncology ◽

10.1007/s12032-021-01479-w ◽

2021 ◽

Vol 38 (4) ◽

Author(s):

Peter Oppelt ◽

Jessica Ley ◽

Mackenzie Daly ◽

Jason Rich ◽

Randal Paniello ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Locally Advanced ◽

Advanced Head ◽

Phase 2 ◽

Phase 2 Trial ◽

A randomised, double-blind, placebo-controlled phase IIa trial of AMG319 given orally as neoadjuvant therapy in patients with human papillomavirus (HPV) positive and negative head and neck squamous cell carcinoma (HNSCC).

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.6068 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 6068-6068 ◽

Cited By ~ 2

Author(s):

Christian H.H Ottensmeier ◽

Terry Jones ◽

Joseph J Sacco ◽

James Anthony McCaul ◽

Peter Brennan ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Human Papillomavirus ◽

Cell Carcinoma ◽

Head And Neck ◽

Neoadjuvant Therapy ◽

Squamous Cell ◽

Double Blind ◽

Double Blind Placebo

Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(21)00136-4 ◽

2021 ◽

Author(s):

Assuntina G Sacco ◽

Ruifeng Chen ◽

Francis P Worden ◽

Deborah J L Wong ◽

Douglas Adkins ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Phase 2 ◽

Open Label ◽

Multicentre Phase ◽

Phase 2 Trial

Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: A double‐blind randomized phase 2 trial

Cancer Medicine ◽

10.1002/cam4.3771 ◽

2021 ◽

Vol 10 (5) ◽

pp. 1681-1689

Author(s):

Jing Huang ◽

Juxiang Xiao ◽

Wentao Fang ◽

Ping Lu ◽

Qingxia Fan ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Esophageal Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Squamous Cell ◽

Phase 2 ◽

Double Blind ◽

Phase 2 Trial ◽

Previously Treated ◽

Randomized phase 2 trial of patritumab (P) or placebo (PBO) + cetuximab (C) + cisplatin (CIS) or carboplatin (CAR) for recurrent and/or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN).

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.6045 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 6045-6045 ◽

Cited By ~ 6

Author(s):

Kevin J. Harrington ◽

Martin David Forster ◽

Christophe Le Tourneau ◽

Jose Ariza ◽

Shuquan Chen ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Phase 2 ◽

Phase 2 Trial ◽

A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma

Cancer ◽

10.1002/cncr.32762 ◽

2020 ◽

Vol 126 (10) ◽

pp. 2146-2152 ◽

Cited By ~ 2

Author(s):

Sara E. Kochanny ◽

Francis P. Worden ◽

Douglas R. Adkins ◽

Dean W. Lim ◽

Julie E. Bauman ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Phase 2 ◽

Phase 2 Trial of AT-101 in Combination With Docetaxel for Recurrent, Locally Advanced, or Metastatic Head-and-Neck Squamous Cell Carcinoma (HNSCC)

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2013.11.140 ◽

2014 ◽

Vol 88 (2) ◽

pp. 507 ◽

Cited By ~ 1

Author(s):

A. Sacco ◽

J. Nor ◽

E. Belile ◽

A. Sukari ◽

D. Chepeha ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Locally Advanced ◽

Phase 2 ◽

Phase 2 Trial

Intralesional SD-101 in combination with pembrolizumab in anti-PD-1 treatment naive head and neck squamous cell carcinoma: results from a multicenter, phase 2 trial

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-21-1411 ◽

2021 ◽

pp. clincanres.1411.2021

Author(s):

Ezra E.W. Cohen ◽

Lisle Nabell ◽

Deborah J. Wong ◽

Terry Day ◽

Gregory A. Daniels ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Phase 2 ◽

Phase 2 Trial ◽

Multicenter Phase ◽

Treatment Naïve

Metastatic Squamous Cell Carcinoma

Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(17)30064-5 ◽

2017 ◽

Vol 18 (3) ◽

pp. 323-335 ◽

Cited By ~ 90

Author(s):

Denis Soulières ◽

Sandrine Faivre ◽

Ricard Mesía ◽

Éva Remenár ◽

Shau-Hsuan Li ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Trial ◽

The Usability of p16 Immunohistochemical Staining as a Screening Test of Human Papillomavirus Infection in Head and Neck Squamous Cell Carcinoma

Korean Journal of Otorhinolaryngology - Head and Neck Surgery ◽

10.3342/kjorl-hns.2010.53.10.620 ◽

2010 ◽

Vol 53 (10) ◽

pp. 620

Author(s):

Moon Oh Kwon ◽

Se-Heon Kim ◽

Jun Yeon Hwang ◽

Sei Young Lee

Keyword(s):

Squamous Cell Carcinoma ◽

Human Papillomavirus ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Screening Test ◽

Immunohistochemical Staining ◽

Human Papillomavirus Infection ◽

Papillomavirus Infection